Rights and permissions
About this article
Cite this article
The HAART of the matter: cutting the cost of Lazarus syndrome. Pharmacoecon. Outcomes News 348, 3–4 (2002). https://doi.org/10.1007/BF03278622
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03278622